The Three P’s: Parotid, PD-L1, and Pembrolizumab
Joint Authors
Wiggins, Amanda
Arter, Zhaohui
Kerns, Tamie
Source
Case Reports in Oncological Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-06-11
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy.
We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.
American Psychological Association (APA)
Wiggins, Amanda& Arter, Zhaohui& Kerns, Tamie. 2019. The Three P’s: Parotid, PD-L1, and Pembrolizumab. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-3.
https://search.emarefa.net/detail/BIM-1141867
Modern Language Association (MLA)
Wiggins, Amanda…[et al.]. The Three P’s: Parotid, PD-L1, and Pembrolizumab. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-3.
https://search.emarefa.net/detail/BIM-1141867
American Medical Association (AMA)
Wiggins, Amanda& Arter, Zhaohui& Kerns, Tamie. The Three P’s: Parotid, PD-L1, and Pembrolizumab. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-3.
https://search.emarefa.net/detail/BIM-1141867
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141867
